FrancophonIA/ELRC3.0 huggingface dataset:
English: Treatment of symptomatic anaemia in adult chronic kidney disease patients Anaemia symptoms and sequelae may vary with age, gender, and overall burden of disease; a physician's evaluation of the individual patient's clinical course and condition is necessary.
Croatian: Liječenje simptomatske anemije u odraslih bolesnika s kroničnom bolesti bubrega Simptomi anemije i njezine posljedice mogu varirati ovisno o dobi, spolu i sveukupnom opterećenju uslijed bolesti; neophodna je liječnička procjena kliničkog tijeka i stanja svakog pojedinog bolesnika.
English: If the amount is too low your doctor may give you an additional iron supplement.
Croatian: Ako je razina preniska, vjerojatno će Vam propisati dodatno uzimanje preparata željeza.
English: Meta-analyses also indicate consistently a significantly increased relative risk of thromboembolic events in cancer patients receiving recombinant human erythropoietin (see section 4.4).
Croatian: Meta-analize također dosljedno pokazuju značajno povećanje relativnog rizika od tromboembolijskih događaja u bolesnika sa zloćudnom bolesti koji primaju rekombinantni humani eritropoetin (vidjeti dio 4.4).
English: Driving and using machines MIRCERA does not affect your ability to drive and use machines.
Croatian: Upravljanje vozilima i strojevima MIRCERA ne utječe na sposobnost upravljanja motornim vozilima i strojevima.
English: In the open-label study there was no difference in overall survival between patients treated with recombinant human erythropoietin and controls.
Croatian: U otvorenom ispitivanju nije bilo razlika u ukupnom preživljenju između bolesnika liječenih rekombinantnim humanim eritropoetinom i kontrola.
English: To ensure effective erythropoiesis, iron status has to be evaluated for all patients prior to and during treatment.
Croatian: Da bi se omogućila učinkovita eritropoeza, u svih bolesnika prije i tijekom liječenja treba provjeravati vrijednosti željeza.
English: MIRCERA is not approved for treatment of patients with chemotherapy induced anaemia (see section 4.1 and 4.4.
Croatian: MIRCERA nije odobrena za liječenje bolesnika s anemijom koja je posljedica kemoterapije (vidjeti dijelove 4.1 i 4.4).
English: There are no data from the use of MIRCERA in pregnant women.
Croatian: Nema podataka o primjeni lijeka MIRCERA u trudnica.
English: There was however a class-related reversible reduction in foetal weight and a decrease in postnatal body-weight gain of offspring at the doses causing exaggerated pharmacodynamic effects in mothers.
Croatian: Međutim, karakteristično za ovu skupinu lijekova, došlo je do reverzibilnog smanjenja težine fetusa i smanjenja postporođajnog prirasta na težini potomaka, pri dozama koje su u majki prouzročile pretjerane farmakodinamičke učinke.
English: The end-user may remove the medicinal product from refrigeration for storage at a room temperature not above 30°C for one single period of 1 month.
Croatian: Krajnji korisnik može izvaditi lijek iz hladnjaka i čuvati ga na sobnoj temperaturi ne višoj od 30°C jednokratno u trajanju do 1 mjeseca.
English: · Do not rub the injection site with dirty hand or cloth.
Croatian: • Nemojte trljati mjesto primjene prljavom rukom ili tkaninom.
English: The strength indicates the quantity of the protein moiety of the methoxy polyethylene glycol-epoetin beta molecule without consideration of the glycosylation.
Croatian: Jačina označava količinu proteinskog dijela molekule metoksi polietilenglikol-epoetina beta, ne uzimajući u obzir glikozilaciju.
English: Blood pressure monitoring: As with other ESAs, blood pressure may rise during treatment with MIRCERA.
Croatian: Praćenje krvnog tlaka: Kao i uz druge LSE, tijekom liječenja lijekom MIRCERA može doći do porasta krvnog tlaka.
English: Physicians may request the Marketing Authorisation Holder to test or re-test serum samples in a reference laboratory for cases of suspected or confirmed AEAB-mediated PRCA or unexplained loss of effect under MIRCERA treatment (e.g. observed clinically by severe anaemia and low reticulocyte count).
Croatian: Liječnici mogu zatražiti od nositelja odobrenja za stavljanje lijeka u promet testiranje ili ponovno testiranje serumskih uzoraka u referentnom laboratoriju u slučaju suspektne ili potvrđene izolirane aplazije crvene krvne loze uzrokovane antieritropoetinskim antitijelima ili nerazjašnjenog gubitka učinka tijekom liječenja lijekom MIRCERA (npr. koji se klinički manifestira teškom anemijom i niskim brojem retikulocita).
English: Caution should be exercised with escalation of MIRCERA doses in patients with chronic renal failure since high cumulative epoetin doses may be associated with an increased risk of mortality, serious cardiovascular and cerebrovascular events.
Croatian: Potreban je oprez prilikom povećanja doza lijeka MIRCERA u bolesnika s kroničnim zatajenjem bubrega jer visoke kumulativne doze epoetina mogu biti povezane s povećanim rizikom od smrtnosti te ozbiljnih kardiovaskularnih i cerebrovaskularnih događaja.
English: SPECIAL STORAGE CONDITIONS Store in a refrigerator
Croatian: Čuvati u hladnjaku
English: Alternatively, your doctor may decide to administer a starting dose of MIRCERA of 0.6 micrograms for every kilogram of your body weight.
Croatian: Alternativno, Vaš liječnik može odlučiti započeti liječenje dozom lijeka MIRCERA od 0,6 mikrograma po svakom kilogramu tjelesne težine.
English: Patients were randomized to stay on their treatment at the time of enrollment or to be switched to MIRCERA in order to maintain stable haemoglobin levels.
Croatian: Bolesnici su randomizirani tako da su u trenutku uključivanja nastavili s liječenjem ili su prebačeni na lijek MIRCERA, kako bi se održale stabilne razine hemoglobina.
English: Like the natural hormone erythropoietin, MIRCERA increases the number of red blood cells and haemoglobin level in your blood.
Croatian: Kao i prirodni hormon eritropoetin, MIRCERA povećava broj eritrocita i razinu hemoglobina u krvi.
English: PHARMACEUTICAL FORM Solution for injection in pre-filled syringe (injection).
Croatian: OBLIK Otopina za injekciju u napunjenoj štrcaljki (injekcija).
English: What you need to know before you use MIRCERA
Croatian: Što morate znati prije nego počnete primjenjivati lijek MIRCERA
English: Overall survival outcome in the trials could not be satisfactorily explained by differences in the incidence of thrombosis and related complications between those given recombinant human erythropoietin and those in the control group.
Croatian: Rezultat ukupnog preživljenja u ispitivanjima ne može se zadovoljavajuće objasniti razlikom u učestalosti tromboze i s njom povezanih komplikacija između ispitanika koji su primali rekombinantni humani eritropoetin i ispitanika u kontrolnoj skupini.
English: Meta-analysis of overall survival data produced a hazard ratio point estimate of 1.06 in favour of controls (95% CI: 1.00, 1.12; 53 trials and 13,933 patients) and for the cancer patients receiving chemotherapy, the overall survival hazard ratio was 1.04 (95% CI: 0.97, 1.11; 38 trials and 10,441 patients).
Croatian: Meta-analiza podataka o ukupnom preživljenju dala je procjenu omjera rizika od 1,06 u korist kontrolnih skupina (95% CI: 1,00; 1,12; 53 ispitivanja i 13 933 bolesnika), dok je u bolesnika sa zloćudnom bolesti koji primaju kemoterapiju omjer rizika za ukupno preživljenje iznosio 1,04 (95% CI: 0,97; 1,11; 38 ispitivanja i 10 441 bolesnik).
English: • It is not known if MIRCERA has a different effect in patients with haemoglobinopathies (disorders associated with abnormal haemoglobin), past or present bleeding, seizures or with a high blood platelet count.
Croatian: • Nije poznato ima li MIRCERA drukčiji učinak na bolesnike s hemoglobinopatijama (poremećaji povezani s abnormalnim hemoglobinom), prisutnim krvarenjem ili krvarenjem u prošlosti, neurološkim napadima ili povišenim brojem trombocita u krvi.
English: MATERIALS Included in the pack: A pre-filled syringe of MIRCERA and a separate injection needle
Croatian: PRIBOR uključen u pakiranje: Napunjena štrcaljka lijeka MIRCERA i zasebna igla za injekciju
English: PRCA in patients with Hepatitis C: A paradoxical decrease in haemoglobin and development of severe anaemia associated with low reticulocyte counts should prompt to discontinue treatment with epoetin and perform anti-erythropoietin antibody testing.
Croatian: PRCA u bolesnika s hepatitisom C: Paradoksalno sniženje hemoglobina i razvoj teške anemije povezane s niskim brojem retikulocita zahtijeva prekid liječenja epoetinom i testiranje na antieritropoetinska antitijela.
English: Keep the syringe dry.
Croatian: Štrcaljku držite suhom.
English: MIRCERA is indicated to treat only the symptomatic anaemia caused by chronic kidney disease.
Croatian: MIRCERA je namijenjena samo za liječenje simptomatske anemije uzrokovane kroničnom bolesti bubrega.
English: · Do not use the pre-filled syringe if syringe, or the plastic tray containing the syringe appears to be damaged.
Croatian: • Nemojte upotrijebiti napunjenu štrcaljku ako se štrcaljka ili plastična plitica u kojoj se štrcaljka nalazi doimaju oštećenima.
English: Only one dose should be administered per syringe.
Croatian: Dopuštena je samo jedna primjena doze po štrcaljki.
English: If you are on dialysis, the recommended starting dose is 0.6 micrograms for every kilogram of your body weight.
Croatian: Ako ste na dijalizi, preporučena početna doza iznosi 0,6 mikrograma po svakom kilogramu tjelesne težine.
English: Take the needle out of the skin WITHOUT releasing the plunger.
Croatian: Izvadite iglu iz kože, ali pritom NE otpuštajte klip.
English: If your healthcare professional has recommended injection of MIRCERA into a vein, you should follow the procedure described below.
Croatian: Ako Vam je zdravstveni radnik preporučio da lijek MIRCERA injicirate u venu, trebate slijediti postupak opisan u nastavku.
English: Take special care with other products that stimulate red blood cell production: MIRCERA is one of a group of products that stimulate the production of red blood cells like the human protein erythropoietin does.
Croatian: Budite posebno oprezni pri korištenju drugih lijekova koji potiču stvaranje crvenih krvnih stanica: MIRCERA je lijek iz skupine lijekova koji potiču stvaranje crvenih krvnih stanica kao što to čini ljudski protein eritropoetin.
English: • Your doctor will check that your haemoglobin does not exceed a certain level, as high haemoglobin could put you at risk of having a problem of the heart or the blood vessels and could increase risk of thrombosis, including pulmonary embolism, myocardial infarction, stroke and death.
Croatian: • Liječnik će provjeriti da Vam hemoglobin ne prelazi određenu razinu jer visoka razina hemoglobina može povećati rizik od poteškoća sa srcem ili krvnim žilama i može povećati rizik od tromboze, uključujući emboliju pluća, infarkt miokarda, moždani udar i smrt.
English: Intercurrent infections, inflammatory or traumatic episodes, occult blood loss, haemolysis, severe aluminium toxicity, underlying haematologic diseases, or bone marrow fibrosis may also compromise the erythropoietic response.
Croatian: Infekcije koje se pojave tijekom liječenja, upalne ili traumatske epizode, okultno krvarenje, hemoliza, teško trovanje aluminijem, otprije postojeće hematološke bolesti ili fibroza koštane srži također mogu oslabiti eritropoetski odgovor.
English: This medicinal product contains less than 1 mmol sodium (23 mg) per ml, i.e. essentialy sodium free.
Croatian: Ovaj lijek sadrži manje od 1 mmol natrija (23 mg) po ml, tj. zanemarive količine natrija.
English: A post-authorisation safety study showed similar incidence rate of stroke between MIRCERA (6.3%) and reference ESAs groups (epoetin alfa, darbepoetin alfa and epoetin beta) (7%).
Croatian: U ispitivanju sigurnosti nakon dobivanja odobrenja opažena je slična incidencija moždanog udara u skupini liječenoj lijekom MIRCERA (6,3%) i skupinama koje su primale referentne lijekove za stimulaciju eritropoeze (epoetin alfa, darbepoetin alfa i epoetin beta) (7%).
English: In case PRCA is diagnosed, therapy with MIRCERA must be discontinued, and patients should not be switched to another recombinant erythropoietic protein (see section 4.4).
Croatian: U slučaju dijagnosticiranja PRCA-e, terapiju lijekom MIRCERA treba prekinuti a bolesnike se ne smije nastaviti liječiti drugim rekombinantnim eritropoetskim proteinom (vidjeti dio 4.4).
English: There is no evidence that MIRCERA interacts with other medicines.
Croatian: Nema dokaza o interakciji lijeka MIRCERA s drugim lijekovima.
English: A comparison of serum concentrations of methoxy polyethylene glycol-epoetin beta measured before and after haemodialysis in 41 CKD patients showed that haemodialysis has no effect on the pharmacokinetics of this medicinal product.
Croatian: Usporedba serumskih koncentracija metoksi polietilenglikol-epoetina beta prije i nakon hemodijalize u 41 bolesnika s kroničnom bolesti bubrega pokazala je da hemodijaliza nema učinak na farmakokinetiku ovog lijeka.
English: Effect on tumour growth: MIRCERA, like other ESAs, is a growth factor that primarily stimulates red blood cell production.
Croatian: Učinak na rast tumora: MIRCERA je, kao i drugi LSE, faktor rasta koji u prvom redu stimulira proizvodnju crvenih krvnih stanica.
English: The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal
Croatian: Zahtjevi za podnošenje PSUR-eva za ovaj lijek definirani su u referentnom popisu datuma EU (EURD popis) predviđenom člankom 107.c stavkom 7. Direktive 2001/83/EZ i svim sljedećim ažuriranim verzijama objavljenima na europskom internetskom portalu za lijekove.
English: Blood pressure should be adequately controlled in all patients before, at initiation of, and during treatment with MIRCERA.
Croatian: U svih bolesnika treba na odgovarajući način kontrolirati krvni tlak prije, na početku i tijekom liječenja lijekom MIRCERA.
English: · Dispose of the full container as instructed by your healthcare provider or pharmacist.
Croatian: • Zbrinite pun spremnik u skladu s uputama koje su Vam dali zdravstveni radnik ili ljekarnik.
English: • Your doctor will check your blood pressure before and during your MIRCERA treatment.
Croatian: • Liječnik će Vam provjeravati krvni tlak prije i tijekom liječenja lijekom MIRCERA.
English: • If you are a patient with hepatitis C and you receive interferon and ribavirin you should discuss this with your doctor because a combination of ESAs with interferon and ribavirin has lead to a loss of effect and development of PRCA, a severe form of anemia, in rare cases.
Croatian: • Ako bolujete od hepatitisa C i primate interferon i ribavirin, morate o tome razgovarati sa svojim liječnikom jer je kombinacija lijekova za stimulaciju eritropoeze s interferonom i ribavirinom u rijetkim slučajevima dovela do gubitka učinka i razvoja teškog oblika anemije (izolirana aplazija crvene krvne loze).
English: MIRCERA has not been studied in pregnant or breast-feeding women.
Croatian: MIRCERA nije ispitivana u trudnica i dojilja.
English: Your doctor may increase or decrease your dose or temporarily stop your treatment to adjust your haemoglobin to an appropriate level for you.
Croatian: Liječnik može povećati ili smanjiti dozu ili privremeno prekinuti liječenje kako bi razinu hemoglobina prilagodio Vama potrebnim vrijednostima.
English: • If you are a patient with chronic renal failure, and particularly if you do not respond properly to MIRCERA, your doctor will check your dose of MIRCERA because repeatedly increasing your dose of MIRCERA if you are not responding to treatment may increase the risk of having a problem of the heart or the blood vessels and could increase risk of myocardial infarction, stroke and death.
Croatian: • Ako ste bolesnik s kroničnom bolesti bubrega, a osobito ako ne odgovarate na lijek MIRCERA na odgovarajući način, Vaš će liječnik provjeriti Vašu dozu lijeka MIRCERA jer opetovano povećavanje doze lijeka MIRCERA, ako ne odgovarate na liječenje, može povećati rizik od problema sa srcem ili krvnim žilama i može povećati rizik od srčanog udara, moždanog udara i smrti.
English: Step 3: Unpack and visually inspect the pre-filled syringe
Croatian: Korak 3: Izvadite i pregledajte napunjenu štrcaljku
English: Once your anaemia iscorrected your doctor may change your dosing to once a month administration.
Croatian: Kada se anemija ublaži, Vaš liječnik može promijeniti učestalost primjene doze na jedanput mjesečno.
English: • if you are allergic to methoxy polyethylene glycol-epoetin beta or to any of the other ingredients of this medicine (listed in section 6)
Croatian: • ako ste alergični na metoksi polietilenglikol-epoetin beta ili neki drugi sastojak ovog lijeka
English: Do not release the plunger before the end of injection or before the plunger is completely depressed.
Croatian: Nemojte otpustiti klip prije završetka injekcije ili prije nego što ga pritisnete do kraja.
English: Table 1: MIRCERA starting doses Previous weekly darbepoetin alfa intravenous or subcutaneous dose (microgram/week)
Croatian: Tablica 1: Početne doze lijeka MIRCERA Prethodna tjedna doza darbepoetina alfa intravenski ili supkutano (mikrogram/tjedan)
English: These studies have shown a consistent unexplained statistically significant excess mortality in patients who have anaemia associated with various common cancers who received recombinant human erythropoietin compared to controls.
Croatian: Ta su ispitivanja pokazala dosljedan, neobjašnjiv, statistički značajan porast mortaliteta u bolesnika kod kojih je anemija bila povezana s raznim čestim vrstama karcinoma i koji su primali rekombinantni humani eritropoetin, u usporedbi s kontrolama.
English: Traceability of MIRCERA: In order to improve the traceability of ESAs, the trade name of the administered ESA should be clearly recorded (or stated) in the patient file.
Croatian: Sljedivost lijeka MIRCERA: Kako bi se unaprijedilo praćenje LSE, treba u bolesnički karton jasno zabilježiti (ili navesti) zaštićeno ime primijenjenog lijeka iz skupine LSE.
English: If you stop using MIRCERA
Croatian: Ako prestanete uzimati lijek MIRCERA
English: After dose interruption a haemoglobin decrease of approximately 0.35 g/dl (0.22 mmol/l) per week is expected.
Croatian: Nakon izostavljanja doze očekuje se smanjenje razine hemoglobina za otprilike 0,35 g/dl (0,22 mmol/l) tjedno.
English: · Do not use the syringe if the contents are cloudy, hazy or contain particles.
Croatian: • Nemojte upotrijebiti štrcaljku ako je njezin sadržaj mutan, magličast ili ako sadrži čestice.
English: In addition, using a panel of human tissues, the in vitro binding of methoxy polyethylene glycol-epoetin beta was only observed in target cells (bone marrow progenitor cells).
Croatian: Uz to, koristeći panel ljudskih tkiva, in vitro vezivanje metoksi polietilenglikol-epoetina beta uočeno je samo na ciljnim stanicama (progenitorskim stanicama koštane srži).
English: • Your doctor may initiate treatment with MIRCERA if your haemoglobin level is 10 g/dl (6.21 mmol/l) or less.
Croatian: • Liječnik može započeti liječenje lijekom MIRCERA ako Vam je razina hemoglobina 10 g/dl (6,21 mmol/l) ili niža.
English: In a randomised, double-blind, placebo-controlled study of 4,038 CRF patients not on dialysis with type 2 diabetes and haemoglobin levels ≤ 11 g/dL, patients received either treatment with darbepoetin alfa to target haemoglobin levels of 13 g/dL or placebo (see section 4.4).
Croatian: U jednom randomiziranom, dvostruko slijepom, placebo kontroliranom ispitivanju koje je obuhvatilo 4038 bolesnika s dijabetesom tipa 2 i kroničnim zatajenjem bubrega koji nisu bili na dijalizi, s razinama hemoglobina ≤ 11 g/dl, bolesnici su primali ili darbepoetin alfa radi podizanja ciljnih razina hemoglobina na 13 g/dl, ili placebo (vidjeti dio 4.4).
English: Patients should be monitored closely to ensure that the lowest approved effective dose of MIRCERA is used to provide adequate control of the symptoms of anaemia whilst maintaining a haemoglobin concentration below or at 12 g/dl (7.45 mmol/l).
Croatian: Bolesnike treba pomno nadzirati kako bi se zajamčila primjena najniže odobrene učinkovite doze lijeka MIRCERA koja omogućava odgovarajuću kontrolu simptoma anemije, a koncentracija hemoglobina istodobno održala ispod ili na 12 g/dl (7,45 mmol/l).
English: • vascular access thrombosis (blood clots in your dialysis access).
Croatian: • tromboza krvožilnog pristupa (krvni ugrušci u pristupu za dijalizu)
English: The study did not meet either primary objective of demonstrating a reduction in risk for all-cause mortality, cardiovascular morbidity, or end stage renal disease (ESRD).
Croatian: Ispitivanje nije postiglo svoj glavni cilj: prikazati smanjenje rizika od smrti bez obzira na uzrok, oboljenja od kardiovaskularnih bolesti ili bolesti bubrega u završnoj fazi.
English: Analysis of the individual components of the composite endpoints showed the following HR (95% CI): death 1.05 (0.92, 1.21), stroke 1.92 (1.38, 2.68), congestive heart failure (CHF) 0.89 (0.74, 1.08), myocardial infarction (MI) 0.96 (0.75, 1.23), hospitalisation for myocardial ischaemia 0.84 (0.55, 1.27), ESRD 1.02 (0.87, 1.18).
Croatian: Analiza pojedinih sastavnica ukupne mjere ishoda pokazala je sljedeće omjere rizika (95%-tni CI): smrt 1,05 (0,92; 1,21), moždani udar 1,92 (1,38; 2,68), kongestivno zatajenje srca 0,89 (0,74; 1,08), infarkt miokarda 0,96 (0,75; 1,23), hospitalizacija zbog ishemije miokarda 0,84 (0,55; 1,27), bolest bubrega u završnoj fazi 1,02 (0,87; 1,18).
English: • If you are currently being treated with another ESA Your doctor may replace your current medicine with MIRCERA.
Croatian: • Ako se trenutno liječite drugim lijekom za stimulaciju eritropoeze Liječnik može zamijeniti Vaš dosadašnji lijek lijekom MIRCERA.
English: Place a sterile cotton ball or gauze over the injection site and press for several seconds.
Croatian: Stavite sterilnu vatu ili gazu na mjesto primjene i pritisnite je na nekoliko sekundi.
English: · Do not throw away used syringes or the puncture-resistant container in household trash and do not recycle them.
Croatian: • Nemojte bacati upotrijebljene štrcaljke ili neprobojni spremnik u kućni otpad i nemojte ih reciklirati.
English: Monthly MIRCERA intravenous or subcutaneous dose (microgram/once monthly)
Croatian: Mjesečna doza lijeka MIRCERA intravenski ili supkutano (mikrogram/jedanput mjesečno)
English: You should discuss options for anemia treatment with your doctor.
Croatian: Posavjetujte se sa svojim liječnikom o mogućnostima liječenja anemije.
English: Four randomized controlled studies were performed in dialysis patients currently treated with darbepoetin alfa or epoetin at the time of enrollment.
Croatian: Provedena su četiri randomizirana kontrolirana ispitivanja u bolesnika na dijalizi koji su u trenutku uključivanja bili liječeni darbepoetinom alfa ili epoetinom.
English: · The contents are cloudy, hazy or contain particles.
Croatian: • ako je sadržaj mutan, magličast ili sadrži čestice
English: The observed terminal elimination half-life was 142 hours in CKD patients not on dialysis.
Croatian: Opaženo terminalno poluvrijeme eliminacije iznosilo je 142 sata u bolesnika s kroničnom bolesti bubrega koji nisu bili na dijalizi.
English: Do not use this medicine after the expiry date which is stated on the outer carton and pre-filled syringe label after ‘EXP'.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na pakiranju i naljepnici napunjene štrcaljke iza „Rok valjanosti“ ili kratice „EXP“.
English: The therapeutic range of MIRCERA is wide.
Croatian: MIRCERA ima širok terapijski raspon.
English: The safety and efficacy of MIRCERA therapy in other indications, including anaemia in patients with cancer, has not been established.
Croatian: Nisu utvrđene sigurnost i djelotvornost liječenja lijekom MIRCERA u drugim indikacijama, uključujući anemiju u bolesnika sa zloćudnim bolestima.